CR9393A - Anticuerpos anti-ccr5 y usos de los mismos - Google Patents

Anticuerpos anti-ccr5 y usos de los mismos

Info

Publication number
CR9393A
CR9393A CR9393A CR9393A CR9393A CR 9393 A CR9393 A CR 9393A CR 9393 A CR9393 A CR 9393A CR 9393 A CR9393 A CR 9393A CR 9393 A CR9393 A CR 9393A
Authority
CR
Costa Rica
Prior art keywords
num
sec
same
cdr1
cdr2
Prior art date
Application number
CR9393A
Other languages
English (en)
Spanish (es)
Inventor
Brandt Michael
Ratri Suryanarayana
Schumacher Ralf
Seeber Stefan
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CR9393A publication Critical patent/CR9393A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CR9393A 2005-04-01 2007-09-24 Anticuerpos anti-ccr5 y usos de los mismos CR9393A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05007138 2005-04-01

Publications (1)

Publication Number Publication Date
CR9393A true CR9393A (es) 2008-02-20

Family

ID=34934663

Family Applications (1)

Application Number Title Priority Date Filing Date
CR9393A CR9393A (es) 2005-04-01 2007-09-24 Anticuerpos anti-ccr5 y usos de los mismos

Country Status (19)

Country Link
US (1) US7615216B2 (de)
EP (2) EP1869087A2 (de)
JP (2) JP4733736B2 (de)
KR (1) KR20070116136A (de)
CN (1) CN101175771A (de)
AR (1) AR052959A1 (de)
AU (1) AU2006228663A1 (de)
BR (1) BRPI0609792A2 (de)
CA (1) CA2603692A1 (de)
CR (1) CR9393A (de)
IL (1) IL186071A0 (de)
MA (1) MA29374B1 (de)
MX (1) MX2007011842A (de)
NO (1) NO20074867L (de)
RU (1) RU2007139953A (de)
SG (1) SG151284A1 (de)
TW (1) TW200720289A (de)
WO (1) WO2006103100A2 (de)
ZA (1) ZA200708332B (de)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007085567A2 (en) * 2006-01-30 2007-08-02 F. Hoffmann-La Roche Ag Synergistic compositions for treating hiv
TW200817438A (en) * 2006-08-17 2008-04-16 Hoffmann La Roche A conjugate of an antibody against CCR5 and an antifusogenic peptide
BRPI0717512A2 (pt) * 2006-09-29 2013-11-19 Hoffmann La Roche Anticorpos contra ccr5 e usos dos mesmos
CL2008000707A1 (es) 2007-03-13 2008-09-22 Hoffmann La Roche Conjugado de polipeptidos antifusogenicos y polipeptidos derivados de la cabeza globular del factor del complemento c1q; composicion farmaceutica que lo comprende; su uso para tratar infecciones viricas; y metodo de produccion.
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
CA2710912A1 (en) * 2008-01-15 2009-07-23 F. Hoffmann-La Roche Ag Afucosylated antibodies against ccr5 and their use
WO2010028798A1 (en) * 2008-09-10 2010-03-18 F. Hoffmann-La Roche Ag Multivalent antibodies
WO2010028796A1 (en) * 2008-09-10 2010-03-18 F. Hoffmann-La Roche Ag Trispecific hexavalent antibodies
JP2012513425A (ja) 2008-12-22 2012-06-14 エフ．ホフマン−ラ ロシュ アーゲー 免疫グロブリンの精製
RU2598248C2 (ru) 2009-04-02 2016-09-20 Роше Гликарт Аг Полиспецифичные антитела, включающие антитела полной длины и одноцепочечные фрагменты fab
EP2417156B1 (de) 2009-04-07 2015-02-11 Roche Glycart AG Trivalente, bispezifische antikörper
TW201100543A (en) 2009-05-27 2011-01-01 Hoffmann La Roche Tri-or tetraspecific antibodies
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
TW201113037A (en) 2009-08-28 2011-04-16 Hoffmann La Roche Antibodies against CDCP1 for the treatment of cancer
TWI412375B (zh) 2009-08-28 2013-10-21 Roche Glycart Ag 人類化抗ｃｄｃｐ１抗體
WO2011026640A1 (en) 2009-09-07 2011-03-10 F. Hoffmann-La Roche Ag Es-ms of glycopeptides for analysis of glycosylation
RU2573915C2 (ru) 2009-09-16 2016-01-27 Дженентек, Инк. Содержащие суперспираль и/или привязку белковые комплексы и их применение
KR20120098911A (ko) 2009-12-22 2012-09-05 로슈 글리카트 아게 항-ｈｅｒ3 항체 및 이의 용도
TW201138821A (en) 2010-03-26 2011-11-16 Roche Glycart Ag Bispecific antibodies
WO2012010582A1 (en) 2010-07-21 2012-01-26 Roche Glycart Ag Anti-cxcr5 antibodies and methods of use
WO2012025530A1 (en) 2010-08-24 2012-03-01 F. Hoffmann-La Roche Ag Bispecific antibodies comprising a disulfide stabilized - fv fragment
MX343114B (es) 2010-10-05 2016-10-25 F Hoffmann-La Roche Ag * Anticuerpos contra la tweak humana y usos de los mismos.
JP5766296B2 (ja) 2010-12-23 2015-08-19 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ポリペプチド−ポリヌクレオチド複合体、およびエフェクター成分の標的化された送達におけるその使用
RU2597288C2 (ru) * 2011-02-23 2016-09-10 Ф. Хоффманн-Ля Рош Аг Антитела против человеческого il33r и их применение
EP2681239B8 (de) 2011-02-28 2015-09-09 F. Hoffmann-La Roche AG Antigenbindende proteine
MX342034B (es) 2011-02-28 2016-09-12 Hoffmann La Roche Proteinas monovalentes que se unen a antigenos.
WO2013024022A1 (en) 2011-08-12 2013-02-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treatment of pulmonary hypertension
EP2758435A1 (de) 2011-09-23 2014-07-30 Roche Glycart AG Bispezifische anti-egfr-/anti-igf-1r-antikörper
EP2764020B1 (de) 2011-10-05 2015-08-12 F. Hoffmann-La Roche AG Verfahren zur antikörper-g1-glykoform-herstellung
MX2014009565A (es) 2012-02-10 2014-11-10 Genentech Inc Anticuerpos monocatenarios y otros heteromultimeros.
CA2869529A1 (en) 2012-05-24 2013-11-28 Raffaella CASTOLDI Multispecific antibodies
MX2014014804A (es) 2012-06-27 2015-02-12 Hoffmann La Roche Metodo para la elaboracion de conjugados de la region fc de anticuerpos que comprenden por lo menos una entidad de union que se une especificamente a un objetivo y usos del mismo.
MX354862B (es) 2012-06-27 2018-03-23 Hoffmann La Roche Método para la producción de entidades dirigidas altamente selectivas hechas a la medida y biespecíficas que contienen dos entidades de unión diferentes.
AR094403A1 (es) 2013-01-11 2015-07-29 Hoffmann La Roche Terapia de combinación de anticuerpos anti-her3
EP3055329B1 (de) 2013-10-11 2018-06-13 F. Hoffmann-La Roche AG Multispezifische antikörper mit domänengetauschten, gemeinsamen, variablen leichten ketten
WO2015082446A1 (en) 2013-12-02 2015-06-11 F. Hoffmann-La Roche Ag Treatment of cancer using an anti-cdcp1 antibody and a taxane
UA117289C2 (uk) 2014-04-02 2018-07-10 Ф. Хоффманн-Ля Рош Аг Мультиспецифічне антитіло
WO2016087416A1 (en) 2014-12-03 2016-06-09 F. Hoffmann-La Roche Ag Multispecific antibodies
US20180206726A1 (en) 2016-12-07 2018-07-26 Progenity Inc. Gastrointestinal tract detection methods, devices and systems
WO2018112264A1 (en) 2016-12-14 2018-06-21 Progenity Inc. Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor
US20210275589A1 (en) 2018-07-13 2021-09-09 Nanjing Legend Biotech Co. Ltd. Co-receptor systems for treating infectious diseases
EP3883635A1 (de) 2018-11-19 2021-09-29 Progenity, Inc. Verfahren und vorrichtungen zur behandlung einer krankheit mit biotherapeutika
WO2021102173A1 (en) * 2019-11-21 2021-05-27 Unity Biotechnology Antibodies directed to tie-2 and methods of use
CN115666704A (zh) 2019-12-13 2023-01-31 比奥拉治疗股份有限公司 用于将治疗剂递送至胃肠道的可摄取装置
US11629196B2 (en) 2020-04-27 2023-04-18 Incelldx, Inc. Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) * 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
JPS63502716A (ja) 1986-03-07 1988-10-13 マサチューセッツ・インステチュート・オブ・テクノロジー 糖タンパク安定性の強化方法
US4791192A (en) * 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
DE3883899T3 (de) * 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
US5202238A (en) * 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5204244A (en) * 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US6743594B1 (en) 1995-06-06 2004-06-01 Human Genome Sciences, Inc. Methods of screening using human G-protein chemokine receptor HDGNR10 (CCR5)
AU3375697A (en) 1996-05-28 1998-01-05 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Cc chemokine receptor 5, antibodies thereto, transgenic animals
US6528625B1 (en) 1996-10-28 2003-03-04 Millennium Pharmaceuticals, Inc. Anti-CCR5 antibodies and kits comprising same
DE69833755T2 (de) 1997-05-21 2006-12-28 Biovation Ltd. Verfahren zur herstellung von nicht-immunogenen proteinen
US6610834B1 (en) 1998-11-18 2003-08-26 Peter I. Lobo Human IgM antibodies to chemokine receptors
US20030099645A1 (en) * 2000-10-10 2003-05-29 Lobo Peter Isaac Naturally occuring IgM antibodies that bind to membrane receptors on lymphocytes
CN1202128C (zh) 1998-12-08 2005-05-18 拜奥威神有限公司 修饰蛋白的免疫原性
DK1144006T3 (da) 1998-12-16 2007-11-26 Progenics Pharm Inc Synergistisk inhibering af HIV-1-fusion og -binding, præparater og antistoffer dertil
HUP0200484A2 (en) 1999-03-11 2002-06-29 Micromet Ag Antibody and chemokine constructs that are directed to ccr5, and their use for treating autoimmune diseases
WO2001042308A2 (en) * 1999-12-08 2001-06-14 Novartis Ag Methods and compositions useful for inhibiting ccr5-dependent infection of cells by hiv-1
AU2265701A (en) 1999-12-16 2001-06-25 Tanox, Inc. Anti-hiv-1 conjugates for treatment of hiv disease
AU2001243145A1 (en) 2000-02-09 2001-08-20 Human Genome Sciences, Inc. Human g-protein chemokine receptor (ccr5) hdgnr10
US20040043033A1 (en) * 2000-05-01 2004-03-04 Green Lorrence H. Method and vaccine for the prevention of AIDS
US7138119B2 (en) 2000-09-15 2006-11-21 Progenics Pharmaceuticals, Inc. Compositions and methods for inhibition of HIV-1 infection
US7005503B2 (en) 2002-02-08 2006-02-28 Genetastix Corporation Human monoclonal antibody against coreceptors for human immunodeficiency virus
US20030165988A1 (en) * 2002-02-08 2003-09-04 Shaobing Hua High throughput generation of human monoclonal antibody against peptide fragments derived from membrane proteins
US20020147147A1 (en) * 2000-11-16 2002-10-10 Karin Molling Nucleic acid molecules encoding a protein interacting with the chemokine receptor CCR5 or other chemokine receptor family members
EP1207202A1 (de) 2000-11-16 2002-05-22 Mölling, Karin, Inst. für med. Virologie der Uni. Zürich Nukleinsäuremoleküle, welche für ein Protein kodieren, das mit dem Chemokinrezeptor oder anderen Mitgliedern der Chemokinrezeptorfamilie interagiert
US7175988B2 (en) * 2001-02-09 2007-02-13 Human Genome Sciences, Inc. Human G-protein Chemokine Receptor (CCR5) HDGNR10
US20030003440A1 (en) * 2001-03-14 2003-01-02 Lucia Lopalco Novel CCR5 epitope and antibodies against it
US20020146415A1 (en) * 2001-04-06 2002-10-10 Olson William C. Methods for inhibiting HIV-1 infection
US7060273B2 (en) 2001-04-06 2006-06-13 Progenics Pharmaceuticals, Inc. Methods for inhibiting HIV-1 infection
EP1450857B1 (de) 2001-10-16 2010-09-15 The Government of the United States of America, represented by The Secretary, Department of Health and Human Services Neutralisierende antikörper gegen hiv mit breiter kreuzreaktion, die mit hilfe von env-cd4-co-rezeptorkomplexen selektiert werden
AU2003209059A1 (en) 2002-02-08 2003-09-02 Genetastix Corporation Human monoclonal antibodies against membrane proteins
US7122185B2 (en) 2002-02-22 2006-10-17 Progenics Pharmaceuticals, Inc. Anti-CCR5 antibody
RU2322454C2 (ru) 2002-02-22 2008-04-20 Проджиникс Фармасьютикалз, Инк. Антитело против ccr5

Also Published As

Publication number Publication date
JP2011079836A (ja) 2011-04-21
ZA200708332B (en) 2009-04-29
AU2006228663A1 (en) 2006-10-05
JP2008533998A (ja) 2008-08-28
KR20070116136A (ko) 2007-12-06
JP4733736B2 (ja) 2011-07-27
CA2603692A1 (en) 2006-10-05
US7615216B2 (en) 2009-11-10
EP2336183A3 (de) 2011-10-12
US20070036796A1 (en) 2007-02-15
SG151284A1 (en) 2009-04-30
BRPI0609792A2 (pt) 2010-04-27
EP1869087A2 (de) 2007-12-26
MA29374B1 (fr) 2008-04-01
RU2007139953A (ru) 2009-05-10
CN101175771A (zh) 2008-05-07
IL186071A0 (en) 2008-01-20
WO2006103100A3 (en) 2006-12-28
TW200720289A (en) 2007-06-01
MX2007011842A (es) 2007-10-11
WO2006103100A2 (en) 2006-10-05
EP2336183A2 (de) 2011-06-22
NO20074867L (no) 2007-12-07
AR052959A1 (es) 2007-04-11

Similar Documents

Publication Publication Date Title
CR9393A (es) Anticuerpos anti-ccr5 y usos de los mismos
ES2547463T3 (es) Moléculas de unión a ILT3 y usos de las mismas
RS54393B1 (en) HUMAN MONOCLONAL ANTIBODIES ON KINASE-1 SIMILAR TO ACTIVE RECEPTOR
PE20120079A1 (es) Moleculas de anticuerpos mejoradas
AR117911A2 (es) Anticuerpo anti-158p1d7 o fragmento de unión a antígeno del mismo, conjugado fármaco-anticuerpo, composición farmacéutica y sus usos
HRP20210170T1 (hr) Protutijela protiv b7-h3 i konjugati protutijela s lijekom
RS52332B (en) HUMAN ANTI-NGF NEUTRAL ANTIBODIES AS SELECTIVE NGF SIGNAL ROUTE INHIBITORS
EA200800812A1 (ru) Композиции антитела против cd3
AR096895A2 (es) Anticuerpo que se une a la citoquina, linfopoyetina estromal tímica (tslp)
PE20191102A1 (es) Anticuerpos anti-pd-1 y sus usos
NZ595235A (en) Compositions and methods for increasing muscle growth
PE20200294A1 (es) Anticuerpos que se unen especificamente a pd-1 y metodos de uso
AR070346A1 (es) Anticuerpo especifico del receptor de linfopoyetina estromal timica (tslpr) y usos en trastornos inflamatorios e inflamatorios alergicos
RS54088B1 (en) B-CELL REDUCTION BY USING CD37-SPECIFIC AND CD20-SPECIFIC BINDING MOLECULES
CL2013003373A1 (es) Proteina de union al antigeno de maduración de linfocitos b (bcma); composicion farmacéutica que comprende la proteína; uso para preparar un medicamento util para tratar mieloma multiple o (mm) leucemia linfocitica cronica (cll).
NZ628528A (en) Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
AR065506A1 (es) Anticuerpos antagonistas ox40 y su uso en el tratamiento de enfermedades
NZ607711A (en) Antibodies directed to her-3 and uses thereof
PE20131403A1 (es) Anticuerpos anti-ox40 y metodos de uso de los mismos
RU2016111137A (ru) Сконструированные конъюгаты против dll3 и способы применения
PE20141398A1 (es) Anticuerpos neutralizantes de citomegalovirus humano
PE20130159A1 (es) Anticuerpos anti-cd40
RS53760B1 (en) HUMAN ANTIBODIES RELATING TO MESOTELINE AND THEIR USES
ATE476994T1 (de) Antikörper gegen gpnmb und ihre verwendungen
RS53750B1 (en) NOTCH1 RECEPTOR BINDING AGENTS AND APPLICATION PROCEDURES

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)